MetaVia (MTVA) Long-Term Deferred Tax (2015 - 2023)
MetaVia's (MTVA) quarterly Long-Term Deferred Tax came in at $2.1 million in Q4 2023, down 52.42% YoY from $4.4 million in Q4 2022, and down 52.42% on a QoQ basis from $4.4 million in Q4 2022.
MetaVia (MTVA) Long-Term Deferred Tax (2015 - 2023) Analysis & Trends
MetaVia (MTVA) has 4 years of Long-Term Deferred Tax data on file, last reported at $2.1 million in Q4 2023.
- Quarterly Long-Term Deferred Tax fell 52.42% year-over-year to $2.1 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $2.1 million (down 52.42% YoY) and the FY2023 annual result came in at $2.1 million, down 52.42% from the prior year.
- Long-Term Deferred Tax declined to $2.1 million in Q4 2023, from $4.4 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $4.4 million in Q4 2022 to a low of $2.1 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 2.11 Mn |
| Dec 31, 2022 | 4.43 Mn |
| Dec 31, 2017 | 6.80 Mn |
| Dec 31, 2015 | 847,000.00 |